Veracyte, Inc.

396 articles with Veracyte, Inc.

• Veracyte Announces Third Quarter 2022 Financial Results

  11/2/2022

  Veracyte, Inc. (Nasdaq: VCYT) today announced financial results for the third quarter ended September 30, 2022.

• Veracyte Announces Three Abstracts to Be Presented at SITC 2022 Annual Meeting

  11/1/2022

  Veracyte, Inc. announced that three abstracts highlighting the company’s unique, multi-omics immuno-oncology capabilities and offerings will be presented at the Society for Immunotherapy of Cancer’s 37th Annual Meeting & Pre-Conference Programs, taking place November 8-12, 2022, in Boston.

• Veracyte to Participate in the Credit Suisse 31st Annual Healthcare Conference

  10/27/2022

  Veracyte, Inc. (Nasdaq: VCYT) announced today that Marc Stapley, chief executive officer, and Rebecca Chambers, chief financial officer, will participate in a fireside chat at the Credit Suisse 31st Annual Healthcare Conference on Tuesday, November 8, at 1:25 p.m. Eastern Time.

• New Data Suggest Decipher GRID-Derived Genomic Signature Can Help Identify Men with Prostate Cancer Who Should Receive High-Dose Radiotherapy

  10/25/2022

  Veracyte, Inc . (Nasdaq: VCYT) announced new data demonstrating that a genomic signature derived from the company’s Decipher GRID database could help determine which men experiencing prostate cancer progression following radical prostatectomy (RP).

• Veracyte Data Presented at ATA Annual Meeting Provide New Insights into Molecular Underpinnings of Thyroid Cancer

  10/24/2022

  Veracyte, Inc. (Nasdaq: VCYT) today announced data that provide new insights into thyroid tumor behavior.

• New Data Presented at CHEST 2022 Reinforce Clinical Value of Veracyte’s Genomic Tests in Interstitial Lung Disease and Lung Cancer

  10/18/2022

  Veracyte, Inc. (Nasdaq: VCYT) today announced that two abstracts highlighting the clinical value of the company’s Envisia Genomic Classifier and Percepta Nasal Swab tests in interstitial lung disease (ILD) and lung cancer, respectively, were presented as posters today at the American College of Chest Physicians (CHEST) Annual Meeting 2022.

• Veracyte to Release Third Quarter 2022 Financial Results on November 2, 2022

  10/13/2022

  Veracyte, Inc. (Nasdaq: VCYT) announced today that it will release financial results for the third quarter of 2022 after the close of market on Wednesday, November 2, 2022.

• New Data Published in JNCI Demonstrate Veracyte’s Decipher Prostate Genomic Classifier May Improve Identification of Aggressive Prostate Cancer in African American Men

  9/22/2022

  Veracyte, Inc. (Nasdaq: VCYT) announced that data published today in the Journal of the National Cancer Institute demonstrate that the company’s Decipher Prostate Genomic Classifier may help identify African American men with early, localized prostate cancer who are most likely to harbor more aggressive disease.

• Veracyte Names John Leite, Ph.D., as General Manager of Pulmonology & Market Access

  9/13/2022

  Veracyte, Inc. (Nasdaq: VCYT) announced today that John Leite, Ph.D., has joined the company as senior vice president and general manager of Pulmonology & Market Access.

• New Data Presented at ESMO 2022 Show Veracyte’s Decipher Prostate Genomic Classifier May Help Inform Personalized Treatment Decisions in Men with Advanced Prostate Cancer

  9/11/2022

  Veracyte, Inc. announced that new data from a Phase 3 trial of the multi-center, multi-national, randomized STAMPEDE platform protocol confirm the ability of the company’s Decipher Prostate Genomic Classifier to identify men with advanced prostate cancer who are more likely to benefit from intensified treatment with abiraterone acetate and prednisolone in addition to standard-of-care androgen-deprivation therapy.

• New Data Suggest Veracyte’s Envisia Genomic Classifier Can Help Predict Disease Progression in Interstitial Lung Disease Patients Treated with Combination Immunosuppressive Therapy

  9/7/2022

  Veracyte, Inc. (Nasdaq: VCYT) today announced new data suggesting that the Envisia Genomic Classifier (EGC) can help predict which patients with interstitial lung disease (ILD), including idiopathic pulmonary fibrosis (IPF), are likely to have progressive disease that declines with combination immunosuppressive therapy.

• Veracyte to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference

  9/1/2022

  Veracyte, Inc. (Nasdaq: VCYT) announced today that Marc Stapley, chief executive officer, and Rebecca Chambers, chief financial officer, will participate in a fireside chat at the Morgan Stanley 20th Annual Global Healthcare Conference on Tuesday, September 13, at 2:55 p.m. Eastern Time.

• Veracyte Announces Seven Abstracts to Be Presented at ESMO Congress 2022

  8/31/2022

  Veracyte, Inc. (Nasdaq: VCYT) announced today that seven abstracts showcasing the company’s genomic tests for prostate (Decipher) and breast (Prosigna) cancers will be presented at the European Society for Medical Oncology (ESMO) Congress 2022, taking place September 9-13, 2022, in Paris.

• New Data in Nature Medicine Suggest Pre-Treatment Tumor Microenvironment Can Impact Response for CAR T-Cell Therapy in Patients with Large B-Cell Lymphoma

  8/29/2022

  New Data in Nature Medicine Suggest Pre-Treatment Tumor Microenvironment Can Impact Response for CAR T-Cell Therapy in Patients with Large B-Cell Lymphoma.

• Veracyte Appoints Eliav Barr, M.D., to Its Board of Directors

  8/11/2022

  Veracyte, Inc. announced the appointment of Eliav Barr, M.D., to its board of directors, effective immediately.

• Veracyte Announces Second Quarter 2022 Financial Results

  8/2/2022

  Veracyte, Inc. (Nasdaq: VCYT) today announced financial results for the second quarter ended June 30, 2022.

• Veracyte Announces New Clinical Validation Data for RNA Sequencing-Based Afirma Medullary Thyroid Cancer Classifier Published in Thyroid

  7/20/2022

  Veracyte, Inc. (Nasdaq: VCYT) today announced that new clinical validation data published online in Thyroid show that the company’s RNA sequencing-based Afirma Medullary Thyroid Cancer (MTC) Classifier demonstrated high sensitivity and specificity in identifying MTC among pre-operative thyroid nodule fine needle aspiration (FNA) biopsy samples.

• New Data Published in PLOS ONE Validate the Clinical Performance of Veracyte’s Percepta Genomic Sequencing Classifier in Lung Cancer Diagnosis

  7/13/2022

  Veracyte, Inc. (Nasdaq: VCYT) announced that new data published today in PLOS ONE show that the company’s Percepta Genomic Sequencing Classifier (GSC) is highly accurate in re-classifying lung cancer risk among patients with lung nodules whose bronchoscopy results are inconclusive.

• Veracyte Named a San Francisco “Bay Area Top Workplace” For Ninth Consecutive Year

  6/27/2022

  Veracyte, Inc. (Nasdaq: VCYT), a global diagnostics company, today announced that it has been named a Bay Area Top Workplace for the ninth consecutive year.

• New Data Show Strong Performance of Veracyte’s Afirma GSC in Real-World Clinical Practice

  6/20/2022

  Veracyte, Inc. (Nasdaq: VCYT) today announced that findings from a new meta-analysis provide real-world evidence that the Afirma Genomic Sequencing Classifier (GSC) can accurately rule out thyroid cancer in patients with indeterminate thyroid nodules and that, when the test deems a nodule as suspicious, the patient’s risk of malignancy is consistent, and higher than that reported in the test’s original clinical validation (CV) study.